Company intelligence / Profile preview

SurgiMab

Montpellier, Occitanie, Francesurgimab.com ↗

Ownership: Private
Employees: ~25
Development stage: Preclinical

Overview

SurgiMab’s lead product SGM‑101, an antibody-fluorophore conjugate targeting CEA, has shown in a Phase 2 trial that it can detect residual and otherwise invisible tumor tissue during surgery. The use of SGM‑101 led to modification of surgery in about one-third of patients with recurrent or peritoneal metastases of colorectal cancer by enabling more aggressive resection or preservation of healthy tissue. The pivotal Phase 3 trial in colorectal cancer patients was ongoing as of the latest reports.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateMonoclonal antibodyBiologic
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

SGM101

Pre-clinical

Indications: Cancer

Partnerships

Plans to commercialize with partners pending approval; specific partners not named as of latest data.

Beyond the preview

Go deeper on SurgiMab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SurgiMab.

Explore the full profile